Literature DB >> 10527832

Presence and expression of a novel variant form of ST2 gene product in human leukemic cell line UT-7/GM.

S i Tominaga1, K Kuroiwa, K Tago, H Iwahana, K Yanagisawa, N Komatsu.   

Abstract

A novel variant cDNA from the human ST2 gene other than ST2 or ST2L was identified and tentatively named ST2V. Alternative splicing inserts a new exon which leads to a change in the C-terminal portion of ST2, causing it to gain a hydrophobic tail instead of losing the third immunoglobulin-like domain. ST2V is expressed in human leukemic cell line UT-7 and its sublines UT-7/GM, UT-7/EPO, and UT-7/TPO, in addition to human helper T cell line 5C10. The amount of ST2V mRNA is greatly diminished when UT-7/GM cells are induced to differentiate into either erythroblastic or megakaryoblastic phenotypes. The possible roles of the ST2V in growth and differentiation are intriguing. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10527832     DOI: 10.1006/bbrc.1999.1469

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  29 in total

1.  Evolutionary conservation of alternative splicing in chicken.

Authors:  S Katyal; Z Gao; R-Z Liu; R Godbout
Journal:  Cytogenet Genome Res       Date:  2007       Impact factor: 1.636

2.  Endogenous IL-33 and Its Autoamplification of IL-33/ST2 Pathway Play an Important Role in Asthma.

Authors:  Jenna M Magat; Joanna L Thomas; Justin P Dumouchel; Fiona Murray; Willis X Li; Jinghong Li
Journal:  J Immunol       Date:  2020-01-27       Impact factor: 5.422

3.  ST2 gene expression is proliferation-dependent and its ligand, IL-33, induces inflammatory reaction in endothelial cells.

Authors:  Shinsuke Aoki; Morisada Hayakawa; Hiromi Ozaki; Naoki Takezako; Hiroto Obata; Nobuhiro Ibaraki; Tadahiko Tsuru; Shin-Ichi Tominaga; Ken Yanagisawa
Journal:  Mol Cell Biochem       Date:  2009-09-12       Impact factor: 3.396

Review 4.  Novel Biomarkers in Heart Failure Beyond Natriuretic Peptides - The Case for Soluble ST2.

Authors:  Antonio J Vallejo-Vaz
Journal:  Eur Cardiol       Date:  2015-07

Review 5.  Implications for Interleukin-33 in solid organ transplantation.

Authors:  Quan Liu; Hēth R Turnquist
Journal:  Cytokine       Date:  2013-03-27       Impact factor: 3.861

Review 6.  Human eosinophils and mast cells: Birds of a feather flock together.

Authors:  Piper A Robida; Pier Giorgio Puzzovio; Hadas Pahima; Francesca Levi-Schaffer; Bruce S Bochner
Journal:  Immunol Rev       Date:  2018-03       Impact factor: 12.988

7.  The IL-33/ST2 axis augments effector T-cell responses during acute GVHD.

Authors:  Dawn K Reichenbach; Vincent Schwarze; Benjamin M Matta; Victor Tkachev; Elisabeth Lieberknecht; Quan Liu; Brent H Koehn; Dietmar Pfeifer; Patricia A Taylor; Gabriele Prinz; Heide Dierbach; Natalie Stickel; Yvonne Beck; Max Warncke; Tobias Junt; Annette Schmitt-Graeff; Susumu Nakae; Marie Follo; Tobias Wertheimer; Lukas Schwab; Jason Devlin; Simon C Watkins; Justus Duyster; James L M Ferrara; Heth R Turnquist; Robert Zeiser; Bruce R Blazar
Journal:  Blood       Date:  2015-03-26       Impact factor: 22.113

8.  Small Molecule Mimetics of α-Helical Domain of IRAK2 Attenuate the Proinflammatory Effects of IL-33 in Asthma-like Mouse Models.

Authors:  Jinghong Li; Kunio Saruta; Justin P Dumouchel; Jenna M Magat; Joanna L Thomas; Dariush Ajami; Mitra Rebek; Julius Rebek; Timothy D Bigby
Journal:  J Immunol       Date:  2018-05-04       Impact factor: 5.422

Review 9.  The IL-33/ST2 pathway: therapeutic target and novel biomarker.

Authors:  Rahul Kakkar; Richard T Lee
Journal:  Nat Rev Drug Discov       Date:  2008-10       Impact factor: 84.694

10.  Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma.

Authors:  Markus Brunner; Claus Krenn; Georg Roth; Bernhard Moser; Martin Dworschak; Erika Jensen-Jarolim; Andreas Spittler; Thomas Sautner; Nico Bonaros; Ernst Wolner; George Boltz-Nitulescu; Hendrik Jan Ankersmit
Journal:  Intensive Care Med       Date:  2004-02-28       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.